1. Kresken, M., Wiedemann, B. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin. Antimicrob. Agents Chemother. 32 (1988) 1285–1288.
2. Wiedemann, B., Zühlsdorf, M. T. Brief report: resistance development to fluoroquinolones in Europe. Am. J. Med. 87 (Suppl. 5A) (1989) 9–11.
3. Kresken, M., Hafner, D., Mittermayer, H., Verbist, L., Bergogne-Bérézin, E., Giamarellou, N., Esposito, S., Van Klingeren, B., Kayser, F. N., Reeves, D. and Study Group of the Paul Ehrlich Society for Chemotherapy, European Study Group ‘Bacterial Resistance’: Prevalence of antibiotic resistance in Europe, 1990. 6th European Congress of Clinical Microbiology and Infectious Diseases, March 1993, Seville, Abstract No. 308.
4. Kresken, M., Haftner, D. and Study Group of the Paul Ehrlich Society for Chemotherapy, European Study Group ‘Bacterial Resistance’: Development of resistance to fluoroquinolones between 1983 and 1990 in central Europe. 6th European Congress of Clinical Microbiology and Infectious Diseases, March 1993, Seville, Abstract No. 1046.
5. Focht, J., Kraus, H., Nosner, K.: Comparativein vitro activity of ofloxacin and other antimicrobial agents used in oral therapy in general practice during the years 1985–1991. 4th International Symposium on New Quinolones, Munich, August 1992, Abstract No. 7.